These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 32054360)

  • 21. Focus on vitamin D therapy in chronic kidney disease.
    Tentori F
    J Nephrol; 2007; 20(5):511-4. PubMed ID: 17918134
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical Epidemiology of Mineral Bone Disorder Markers in Prevalent Hemodialysis Patients in the Xinjiang Uyghur Autonomous Region in China.
    Sun YP; Yang WJ; Li SH; Han YY; Liu J
    Biomed Res Int; 2017; 2017():2516934. PubMed ID: 28299319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of extended hours dialysis on markers of chronic kidney disease-mineral and bone disorder in the ACTIVE Dialysis study.
    Zhan Z; Smyth B; Toussaint ND; Gray NA; Zuo L; de Zoysa JR; Chan CT; Jin C; Scaria A; Hawley CM; Perkovic V; Jardine MJ; Zhang L
    BMC Nephrol; 2019 Jul; 20(1):258. PubMed ID: 31299919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnosis and management of mineral and bone disorders in infants with CKD: clinical practice points from the ESPN CKD-MBD and Dialysis working groups and the Pediatric Renal Nutrition Taskforce.
    Bacchetta J; Schmitt CP; Bakkaloglu SA; Cleghorn S; Leifheit-Nestler M; Prytula A; Ranchin B; Schön A; Stabouli S; Van de Walle J; Vidal E; Haffner D; Shroff R
    Pediatr Nephrol; 2023 Sep; 38(9):3163-3181. PubMed ID: 36786859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real World Use and Effects of Calcimimetics in Treating Mineral and Bone Disorder in Hemodialysis Patients.
    Danese MD; Lubeck D; Belozeroff V; Lin TC; Desai P; Gleeson M; Martin K; Chonchol M
    Am J Nephrol; 2020; 51(10):815-822. PubMed ID: 32966995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between serum calcium or phosphate levels and mortality stratified by parathyroid hormone level: an analysis from the MBD-5D study.
    Asada S; Yokoyama K; Miyakoshi C; Fukuma S; Endo Y; Wada M; Nomura T; Onishi Y; Fukagawa M; Fukuhara S; Akizawa T
    Clin Exp Nephrol; 2020 Jul; 24(7):630-637. PubMed ID: 32236781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detecting high-risk chronic kidney disease-mineral bone disorder phenotypes among patients on dialysis: a historical cohort study.
    Neri L; Kreuzberg U; Bellocchio F; Brancaccio D; Barbieri C; Canaud B; Stuard S; Ketteler M
    Nephrol Dial Transplant; 2019 Apr; 34(4):682-691. PubMed ID: 30165528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effect of Ronghuang Granule on serum FGF23, FGFRs and Klotho in non-dialysis patients with CKD-MBD and kidney deficiency and damp-heat syndrome].
    Hu S; Wang D; Zhang R; Cao Y; Jin H; Mao Y; Wei L; Ren K; Zhang X; Wang Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2018 Dec; 38(12):1427-1432. PubMed ID: 30613009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trabecular bone score may indicate chronic kidney disease-mineral and bone disorder (CKD-MBD) phenotypes in hemodialysis patients: a prospective observational study.
    Yun HJ; Ryoo SR; Kim JE; Choi YJ; Park I; Shin GT; Kim H; Jeong JC
    BMC Nephrol; 2020 Jul; 21(1):299. PubMed ID: 32711466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The interplay between bone and vessels in pediatric CKD: lessons from a single-center study.
    Preka E; Ranchin B; Doyon A; Vierge M; Ginhoux T; Kassai B; Bacchetta J
    Pediatr Nephrol; 2018 Sep; 33(9):1565-1575. PubMed ID: 29872964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence and pattern of renal osteodystrophy in chronic hemodialysis patients: a cross sectional study of 103 patients.
    Buargub MA; Nabulsi MF; Shafeh TA
    Saudi J Kidney Dis Transpl; 2006 Sep; 17(3):401-7. PubMed ID: 16970264
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Facility-level CKD-MBD composite score and risk of adverse clinical outcomes among patients on hemodialysis.
    Block GA; Yusuf AA; Danese MD; Wirtz HS; Hu Y; Do TP; Cooper K; Gilbertson DT; Bradbury BD; Collins AJ
    BMC Nephrol; 2016 Nov; 17(1):166. PubMed ID: 27814753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum markers of low-turnover bone disease in Mexican children with chronic kidney disease undergoing dialysis.
    Avila-Díaz M; Matos M; García-López E; Prado MD; Castro-Vázquez F; Ventura MD; González E; Amato D; Paniagua R
    Perit Dial Int; 2006; 26(1):78-84. PubMed ID: 16538879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trends of elevated parathormone serum titers in hemodialysis patients on intensive therapy for bone disease: a multicenter study.
    Karkar A; Sinha AK; Abdelrahman M; Mushtaque F; Awn NM; Qadi Y; Nassar M; Algareeb A; Taha MI; Abdulkader M; Sabry A; Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2014 Nov; 25(6):1166-77. PubMed ID: 25394432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Uremic Toxicity and Bone in CKD.
    Yamamoto S; Fukagawa M
    J Nephrol; 2017 Oct; 30(5):623-627. PubMed ID: 28573386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between the Achievement of Target Range CKD-MBD Markers and Mortality in Prevalent Hemodialysis Patients in Taiwan by Using the Kidney Disease: Improving Global Outcomes Clinical Guidelines.
    Liu Y; Lee WC; Cheng BC; Li LC; Lee CH; Chang WX; Chen JB
    Biomed Res Int; 2016; 2016():1523124. PubMed ID: 28003998
    [No Abstract]   [Full Text] [Related]  

  • 37. CKD-Mineral Bone Disorder in Stage 4 and 5 CKD: What We Know Today?
    Melamed ML; Buttar RS; Coco M
    Adv Chronic Kidney Dis; 2016 Jul; 23(4):262-9. PubMed ID: 27324680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adherence to Kidney Disease: Improving Global Outcomes Mineral and Bone Guidelines for Monitoring Biochemical Parameters.
    Roetker NS; Peng Y; Ashfaq A; Gilbertson DT; Wetmore JB
    Am J Nephrol; 2019; 49(3):225-232. PubMed ID: 30820015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of L-Carnitine on Mineral Metabolism in the Multicentre, Randomized, Double Blind, Placebo-Controlled CARNIDIAL Trial.
    Mercadal L; Tezenas du Montcel S; Chonchol MB; Debure A; Depreneuf H; Servais A; Bassilios N; Assogba U; Allouache M; Prié D
    Am J Nephrol; 2018; 48(5):349-356. PubMed ID: 30408788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Longitudinal Evolution of Markers of Mineral Metabolism in Patients With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.
    Isakova T; Cai X; Lee J; Mehta R; Zhang X; Yang W; Nessel L; Anderson AH; Lo J; Porter A; Nunes JW; Negrea L; Hamm L; Horwitz E; Chen J; Scialla JJ; de Boer IH; Leonard MB; Feldman HI; Wolf M;
    Am J Kidney Dis; 2020 Feb; 75(2):235-244. PubMed ID: 31668375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.